Clinical Trials Logo

Clinical Trial Summary

This study is a single-arm, open-label, dose-escalation clinical trial aimed at exploring the safety, tolerability, and pharmacokinetic characteristics of the CLL-1 CAR NK cells, as well as providing preliminary observations on its efficacy in subjects with relapsed/refractory acute myeloid leukemia.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06307054
Study type Interventional
Source Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Contact
Status Recruiting
Phase Phase 1
Start date March 15, 2024
Completion date March 15, 2027

See also
  Status Clinical Trial Phase
Active, not recruiting NCT06141304 - Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT Phase 2
Active, not recruiting NCT05029141 - New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Phase 2
Completed NCT03848754 - Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Not yet recruiting NCT06007911 - Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT04722952 - PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine,Cytarabine, G-CSF for Refractory or Relapsed AML Phase 3
Withdrawn NCT03932318 - Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients Phase 1/Phase 2
Recruiting NCT04310592 - Natural Killer Cell (CYNK-001) Infusions in Adults With AML Phase 1
Recruiting NCT05237258 - Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia N/A
Active, not recruiting NCT04139434 - Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML Phase 1
Completed NCT05193448 - A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE
Recruiting NCT03867682 - Venetoclax and Lintuzumab-Ac225 in AML Patients Phase 1/Phase 2
Recruiting NCT06022003 - Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia Phase 2
Recruiting NCT03091933 - Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) Phase 1/Phase 2
Active, not recruiting NCT04330820 - Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX) Phase 1/Phase 2
Recruiting NCT05305859 - Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML Phase 2
Approved for marketing NCT03245424 - Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation